BeOne Medicines Ltd.
ONCBeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
Drugs in Pipeline
12
Phase 3 Programs
9
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
ONC Earnings Report
EPS Est: $1.40 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ONC's past catalysts played out
BGB-16673
B-cell Malignancy
Tislelizumab
Advanced Malignancies
BGB-43395
HR+/HER2- Breast Cancer
Tacrolimus
Primary Membranous Nephropathy
Subcutaneous Tislelizumab
Metastatic Gastric Adenocarcinoma
Pirtobrutinib
Chronic Lymphocytic Leukemia
Venetoclax
CLL
Bendamustine
CLL
Sonrotoclax
Mantle Cell Lymphoma
Dexamethasone
Relapsed/Refractory Multiple Myeloma
Zanubrutinib
Chronic Lymphocytic Leukemia
Capecitabine
Advanced Unresectable Gastric Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BGB-16673 | Phase 3 | B-cell Malignancy | - | - |
Tislelizumab | Phase 3 | Advanced Malignancies | - | - |
BGB-43395 | Phase 3 | HR+/HER2- Breast Cancer | - | - |
Tacrolimus | Phase 3 | Primary Membranous Nephropathy | - | - |
Subcutaneous Tislelizumab | Phase 3 | Metastatic Gastric Adenocarcinoma | - | - |
Pirtobrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Venetoclax | Phase 3 | CLL | - | - |
Bendamustine | Phase 3 | CLL | - | - |
Sonrotoclax | Phase 3 | Mantle Cell Lymphoma | - | - |
Dexamethasone | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Capecitabine | Phase 2 | Advanced Unresectable Gastric Adenocarcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BeOne Medicines Ltd.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in BeOne Medicines Ltd.'s (ONC) pipeline across Phase 3, Phase 2. Its lead program is BGB-16673 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BeOne Medicines Ltd.'s next FDA catalyst?→
BeOne Medicines Ltd.'s (ONC) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ONC biotech catalysts?→
Add ONC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BeOne Medicines Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.